Journal
CARDIOLOGY IN REVIEW
Volume 17, Issue 4, Pages 198-200Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CRD.0b013e3181a857ba
Keywords
clopidogrel; proton pump inhibitors; PPI; interaction; Plavix; adverse outcomes
Categories
Ask authors/readers for more resources
Dual antiplatelet therapy with clopidogrel and aspirin has been shown to reduce recurrent cardiac events in patients with acute coronary syndromes or those who have undergone coronary artery stent placement. Clopidogrel, a thienopyridine, is a prodrug that is transformed in vivo to an active metabolite by the cytochrome P450 enzyme system. Due to the increased risk of bleeding in patients on dual antiplatelet therapy, concomitant gastrointestinal ulcer prophylaxis with a proton pump inhibitor (PPI) is frequently prescribed. Data from recent studies show that PPIs, which are extensively metabolized by the cytochrome system, may decrease the antiplatelet activity of clopidogrel. This article reviews the metabolism of various PPIs and existing data regarding the drug-drug interaction between PPIs and clopiclogrel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available